dc.contributor.author |
Matsabisa, MG
|
|
dc.contributor.author |
Alexandre, Kabamba B
|
|
dc.contributor.author |
Ibeji, CU
|
|
dc.contributor.author |
Tripathy, S
|
|
dc.contributor.author |
Erukainure, OL
|
|
dc.contributor.author |
Malatji, Kanyane
|
|
dc.contributor.author |
Chauke, Sipho H
|
|
dc.contributor.author |
Okole, Blessed N
|
|
dc.contributor.author |
Chabalal, HB
|
|
dc.date.accessioned |
2022-09-05T06:37:51Z |
|
dc.date.available |
2022-09-05T06:37:51Z |
|
dc.date.issued |
2022-06 |
|
dc.identifier.citation |
Matsabisa, M., Alexandre, K.B., Ibeji, C., Tripathy, S., Erukainure, O., Malatji, K., Chauke, S.H. & Okole, B.N. et al. 2022. In vitro study on efficacy of PHELA, an African traditional drug against SARS-CoV-2. <i>Scientific Reports, 12.</i> http://hdl.handle.net/10204/12486 |
en_ZA |
dc.identifier.issn |
2045-2322 |
|
dc.identifier.uri |
10.1038/s41598-022-13599-y
|
|
dc.identifier.uri |
http://hdl.handle.net/10204/12486
|
|
dc.description.abstract |
In 2019, coronavirus has made the third apparition in the form of SARS-CoV-2, a novel strain of coronavirus that is extremely pathogenic and it uses the same receptor as SARS-CoV, the angiotensin converting enzyme 2 (ACE2). However, more than 182 vaccine candidates have been announced; and 12 vaccines have been approved for use, although, even vaccinated individuals are still vulnerable to infection. In this study, we investigated PHELA, recognized as an herbal combination of four exotic African medicinal plants namely; Clerodendrum glabrum E. Mey. Lamiaceae, Gladiolus dalenii van Geel, Rotheca myricoides (Hochst.) Steane & Mabb, and Senna occidentalis (L.) Link; as a candidate therapy for COVID-19. In vitro testing found that PHELA inhibited> 90% of SARS-CoV-2 and SARS CoV infection at concentration levels of 0.005 mg/ml to 0.03 mg/ml and close to 100% of MERS-CoV infection at 0.1 mg/ml to 0.6 mg/ml. The in vitro average IC50 of PHELA on SARS-COV-2, SARS-CoV and MERS-COV were ~ 0.01 mg/ml. Secondly in silico docking studies of compounds identifed in PHELA showed very strong binding energy interactions with the SARS-COV-2 proteins. Compound 5 showed the highest afnity for SARS-COV-2 protein compared to other compounds with the binding energy of - 6.8 kcal mol-1. Our data showed that PHELA has potential and could be developed as a COVID-19 therapeutic. |
en_US |
dc.format |
Fulltext |
en_US |
dc.language.iso |
en |
en_US |
dc.relation.uri |
https://pubmed.ncbi.nlm.nih.gov/35718800/ |
en_US |
dc.source |
Scientific Reports, 12 |
en_US |
dc.subject |
SARS-CoV-2 |
en_US |
dc.subject |
Coronavirus |
en_US |
dc.subject |
PHELA |
en_US |
dc.subject |
African traditional drugs |
en_US |
dc.title |
In vitro study on efficacy of PHELA, an African traditional drug against SARS-CoV-2 |
en_US |
dc.type |
Article |
en_US |
dc.description.pages |
12 |
en_US |
dc.description.note |
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. |
en_US |
dc.description.cluster |
Next Generation Health |
en_US |
dc.description.cluster |
Advanced Agriculture & Food |
en_US |
dc.description.impactarea |
Array Print Compan Diagnostics |
en_US |
dc.description.impactarea |
Agro processing |
en_US |
dc.identifier.apacitation |
Matsabisa, M., Alexandre, K. B., Ibeji, C., Tripathy, S., Erukainure, O., Malatji, K., ... Chabalal, H. (2022). In vitro study on efficacy of PHELA, an African traditional drug against SARS-CoV-2. <i>Scientific Reports, 12</i>, http://hdl.handle.net/10204/12486 |
en_ZA |
dc.identifier.chicagocitation |
Matsabisa, MG, Kabamba B Alexandre, CU Ibeji, S Tripathy, OL Erukainure, Kanyane Malatji, Sipho H Chauke, Blessed N Okole, and HB Chabalal "In vitro study on efficacy of PHELA, an African traditional drug against SARS-CoV-2." <i>Scientific Reports, 12</i> (2022) http://hdl.handle.net/10204/12486 |
en_ZA |
dc.identifier.vancouvercitation |
Matsabisa M, Alexandre KB, Ibeji C, Tripathy S, Erukainure O, Malatji K, et al. In vitro study on efficacy of PHELA, an African traditional drug against SARS-CoV-2. Scientific Reports, 12. 2022; http://hdl.handle.net/10204/12486. |
en_ZA |
dc.identifier.ris |
TY - Article
AU - Matsabisa, MG
AU - Alexandre, Kabamba B
AU - Ibeji, CU
AU - Tripathy, S
AU - Erukainure, OL
AU - Malatji, Kanyane
AU - Chauke, Sipho H
AU - Okole, Blessed N
AU - Chabalal, HB
AB - In 2019, coronavirus has made the third apparition in the form of SARS-CoV-2, a novel strain of coronavirus that is extremely pathogenic and it uses the same receptor as SARS-CoV, the angiotensin converting enzyme 2 (ACE2). However, more than 182 vaccine candidates have been announced; and 12 vaccines have been approved for use, although, even vaccinated individuals are still vulnerable to infection. In this study, we investigated PHELA, recognized as an herbal combination of four exotic African medicinal plants namely; Clerodendrum glabrum E. Mey. Lamiaceae, Gladiolus dalenii van Geel, Rotheca myricoides (Hochst.) Steane & Mabb, and Senna occidentalis (L.) Link; as a candidate therapy for COVID-19. In vitro testing found that PHELA inhibited> 90% of SARS-CoV-2 and SARS CoV infection at concentration levels of 0.005 mg/ml to 0.03 mg/ml and close to 100% of MERS-CoV infection at 0.1 mg/ml to 0.6 mg/ml. The in vitro average IC50 of PHELA on SARS-COV-2, SARS-CoV and MERS-COV were ~ 0.01 mg/ml. Secondly in silico docking studies of compounds identifed in PHELA showed very strong binding energy interactions with the SARS-COV-2 proteins. Compound 5 showed the highest afnity for SARS-COV-2 protein compared to other compounds with the binding energy of - 6.8 kcal mol-1. Our data showed that PHELA has potential and could be developed as a COVID-19 therapeutic.
DA - 2022-06
DB - ResearchSpace
DP - CSIR
J1 - Scientific Reports, 12
KW - SARS-CoV-2
KW - Coronavirus
KW - PHELA
KW - African traditional drugs
LK - https://researchspace.csir.co.za
PY - 2022
SM - 2045-2322
T1 - In vitro study on efficacy of PHELA, an African traditional drug against SARS-CoV-2
TI - In vitro study on efficacy of PHELA, an African traditional drug against SARS-CoV-2
UR - http://hdl.handle.net/10204/12486
ER -
|
en_ZA |
dc.identifier.worklist |
25874 |
en_US |